Terumo and Propofol Injectable, page-53

9 November 2017, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to announce it has reached several key milestones in the development of a TPM®/Propofol injection.
In July 2016 Phosphagenics and Terumo signed a Joint R&D Agreement to further optimise the world’s first transparent formulation of propofol, initially developed by Phosphagenics leveraging its proprietary TPM® technology. Over the past 15 months the parties have closely collaborated to further the development of this product.
Earlier this year the parties finalised a formulation that has been successfully taken through a battery of in vitro assays, including 6-month real-time (room temperature) and accelerated (40°C) stability, indicating the potential for a 2-year shelf life. The parties have also shown that the TPM®/Propofol formulation is compatible with several common diluents used during the infusion process.
The collaboration has allowed the parties to generate two separate patent applications, which will be progressed in all key territories. The first of these is a Phosphagenics patent intended to protect the use of TPM® in a range of injectable formulations. The second is a joint Phosphagenics-Terumo patent specifically for the TPM®/Propofol formulation.

..It's TPM sport